Objective: This study aims to estimate the risk of hot flashes relative to natural menopause and to evaluate the associations of hormone levels, behavioral variables, and demographic variables with the risk of hot flashes after menopause.
H ot flashes are widely accepted as the cardinal and most troublesome symptom of menopause and are experienced to some degree by most women as their reproductive years end. 1, 2 Hormone therapy continues to be the primary treatment for the medical management of hot flashes. However, its risks, which were identified in the Women's Health Initiative trials, 3 now limit its use for menopausal symptoms to Bthe shortest period or time[ (Bnot to exceed 3 to 5 years[ in the guidelines of The North American Menopause Society). 4 Empirical evidence supporting the recommended 3-to 5-year hormone therapy for management of hot flashes is lacking. This study was motivated by previous studies, which suggested that hot flashes continued for more than 5 years in some women but which did not consistently identify the prevalence of moderate/severe hot flashes after the final menstrual period (FMP) or the risks for hot flashes that extended beyond 5 years after the FMP. In a meta-analysis of primarily cross-sectional studies, nearly half of the women reported hot flashes 4 years after the FMP, and 10% reported symptoms 10 years after the FMP. 5 In a study of Australian women, the mean duration of hot flashes from symptom onset to study endpoint was 5.2 years, 6 but the duration after menopause, which is a key marker for medical management, was not identified. A survey of more than 8,000 Latin-American women indicated that more than 60% reported vasomotor symptoms 12 years after menopause. 7 We previously reported that the total median duration of hot flashes was 10.2 years when estimated from symptom onset in the late reproductive years through the menopausal transition. 8 In that study, the prospective identification of hot flashes in the early menopausal transition contributed strongly to their long duration. However, many participants had not progressed beyond menopause, and the duration of hot flashes after the FMP, which is the most common period for medical management, was not well characterized.
Data are now available to examine the prevalence and risks of hot flashes in the postmenopausal years. This study estimated the prevalence of hot flashes in relation to the FMP and evaluated risk factors for hot flashes that continued more than 5 years after the FMP. We also explored whether these risk factors predicted a short or long continuation of hot flashes (ie, more than 3-5 y) after the FMP. The cutoff points for time after the FMP were guided by the data and provided empirical support for recent revisions in early-and late-stage postmenopause that were presented in the Stages of Reproductive Aging Workshop (STRAW) + 10 staging of reproductive aging. 9 
METHODS

Study participants
The study evaluated 255 women in the Penn Ovarian Aging Study who reached natural menopause during a 16-year follow-up period (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) . We included only participants who reached natural menopause to address our primary aim of estimating the risk of hot flashes in relation to the FMP. Comparisons of study variables at baseline between the sample and the remainder of the cohort who were not observed to reach natural menopause during the study (n = 181) showed no significant differences, with the exception of age, which was older in the study group at baseline (42.2 vs 40.4 y, P G 0.001).
The full cohort of 436 women was randomly identified by telephone digit dialing in Philadelphia County, PA, using stratified sampling to obtain equal numbers of African-American and white women, as previously described. 10 At enrollment, all women were premenopausal, had regular menstrual cycles of 22 to 35 days for the previous three cycles, were aged 35 to 48 years, and had intact uterus and at least one ovary. Exclusion criteria at cohort enrollment included current use of any hormonal or psychotropic medications, alcohol or drug abuse, major psychiatric disorder in the past year, pregnancy or breastfeeding, uncontrolled hypertension, and serious health problems known to compromise ovarian function. The institutional review board of the University of Pennsylvania approved the study, and all participants provided a written informed consent form.
Study design
After cohort enrollment, follow-up assessments were conducted for 16 years at intervals of approximately 9 months in the first 5 years and then annually, with a 2-year gap between assessments 10 and 11. Study data were collected at two in-home visits, which were timed to the early follicular phase of the menstrual cycle (days 2-6) in two consecutive menstrual cycles, or approximately 1 month apart in noncycling women for 14 assessment periods. Assessments 15 and 16 were conducted by telephone interview. The study was described to participants as a general women's health study. Trained research interviewers obtained menstrual dates, structured interview data on overall health, blood samples for hormone assays, and anthropometric measures. Participants completed a set of validated self-report measures to assess health and other behavioral measures of the study at each assessment period.
Study variables
The primary outcome variable, moderate/severe hot flashes, was reported by the participants at each follow-up period, using a validated menopausal symptom list embedded in the structured interview questionnaire. 11 At each follow-up, the interviewer asked whether hot flashes or night sweats occurred in the past month, asked whether they occurred in the past year, and asked them to rate their severity (0, none; 1, mild; 2, moderate; 3, severe). Time in years was evaluated in relation to the FMP. The FMP was identified after 12 months or more of no menstrual bleeding and was designated as time 0 for each woman to allow for a longitudinal evaluation of hot flashes each year before the FMP (up to, but not including, time 0) and from the FMP onward. Cessation of moderate/severe hot flashes was defined as no moderate/severe hot flashes reported for at least 1 year. Any hot flashes (mild, moderate, or severe) were evaluated in the same manner as a secondary outcome.
Estradiol and follicle-stimulating hormone (FSH) were measured by radioimmunoassay in the Clinical and Translational Research Center of the University of Pennsylvania, using Coat-A-Count commercial kits (Siemens Healthcare Diagnostics, Tarrytown, NY). Blood samples were collected at each study visit (providing a possible maximum of 28 samples per woman), centrifuged, and frozen in aliquots at j80-C. Assays were conducted in batches, which included four visits per participant, to reduce the within-woman variability resulting from assay conditions. All assays were performed in duplicate and repeated if values differed by more than 15%. Interassay and intra-assay coefficients of variation were less than 5%.
Other covariate selections were based on previously determined associations with hot flashes and the aims of this study: current age, age at the FMP, race (self-reported African American or white), body mass index (BMI; Q30 kg/m 2 , G30 kg/m 2 ), alcohol use one or more times per week (yes, no), current smoking (yes, no), currently employed (yes, no), education (more than high school, high school or less), and history of depression as assessed by medical history at enrollment in the cohort. Validated self-report questionnaires included the Zung anxiety index, 12 Center for Epidemiologic StudiesV Depression Scale, 13 Perceived Stress Scale, 14 and physical health as rated on the SF-12 Health Survey. 15 Each scale provided continuous scores for analysis. Higher scores indicated more symptoms, with the exception of the SF-12 Health Survey, where higher scores indicated better health.
Statistical analysis
Longitudinal evaluation of the 255 participants in each study year provided 3,856 outcome reports for analysis. Forty percent of the sample had more than 6 years of observations after the FMP, and 11% had more than 10 years of observations after the FMP. All available data were included in the analysis. Generalized linear mixed-effects regression models for repeated measures were used to estimate the bivariable and multivariable associations of study variables with moderate/ severe hot flashes. Variance estimates for statistical tests on regression coefficients were adjusted for repeated observations from each participant using generalized estimating equations. 16 All models were adjusted for time, which was defined in three segments relative to the FMP: (1) premenopauseVeach year before the FMP (up to, but not including, time 0); (2) early postmenopauseVFMP (time 0) to less than 6 years after the FMP; and (3) late postmenopauseV6 years or more after the FMP (see cutoff point definitions below). This three-level categorical variable was included in each model. For each participant, the total duration of hot flashes was calculated from her first report of moderate/severe hot flashes to her last observed report of moderate/severe hot flashes on follow-up. Observations of hot flashes at the last available assessment were considered censored. Hot flashes were also censored at times of reported hormone use, pregnancy, or breast-feeding in all models. The present sample included no observations of hysterectomy or bilateral oophorectomy inasmuch as only women who reached natural menopause were included, as described above. The models were repeated to evaluate a secondary cutoff point at 3 years or less after menopause and had nearly identical results.
All covariates were defined a priori. Each covariate was added singly to the basic model with time and to the interaction with time. All potentially time-varying covariates were treated as such in modeling. Covariates that were associated with hot flashes at P e 0.20 were included in multivariable models to determine the independent contribution of the covariates to the outcome of hot flashes. Inclusion in the final multivariable models was guided by whether each variable remained statistically significant at P e 0.05 or modified other significant associations by more than 15%. Hypothesized interactions with time were examined for BMI, race, and hormones. No three-way interactions met the inclusion criteria.
The cutoff points for early and late postmenopause were identified from estimates of hot flashes at each postmenopausal year relative to the FMP (Fig. 1 ). The cutoff point on year 6 after the FMP had the largest symptom decrease from the FMP (with a reliable sample size) and was consistent with the cutoff point between early and late postmenopause suggested in the revised STRAW + 10 staging. 9 The secondary cutoff point on year 3 after the FMP had the first (but smaller) decrease from the peak hot flash estimates and was consistent with the cutoff point in early postmenopause suggested in STRAW + 10.
Hormone levels were modeled using natural log transformations to reduce the influence of large values. The subject mean of the two hormone measures obtained at each assessment period was used in the analysis. Hormones were entered separately in multivariable models owing to their high correlation. In the exploratory model, the rate of change for each hormone (slope) before the FMP was used to predict hot flash duration after the FMP. The rate of change was calculated for each woman as the linear regression line for all points in the observed linear range before the FMP, as previously described. 17 Odds ratios (ORs) for the hormones are presented for every one-unit (SD) change in log hormone.
An exploratory analysis of short versus long continuation of hot flashes after the FMP included 158 participants who had moderate/severe hot flashes for at least 1 year after the FMP. The short continuation group included participants whose moderate/severe hot flashes were observed to end within the 3-year follow-up interval. Participants whose follow-up ended before 3 years and reported moderate/severe hot flashes at their last observation were excluded because it was not possible to define the cessation of moderate/severe hot flashes within the 3-year interval for these women. Also, we excluded participants who had post-FMP follow-up that was insufficient to accurately determine the cessation of hot flashes within the first 3 years after the FMP. Participants who had moderate/ severe hot flashes for more than 3 years after the FMP composed the long continuation group.
Statistical power calculations were computed using STATA version 12 (STATA, College Station, TX). Assumptions were based on data in the cohort and included a 35% risk of hot flashes for the unexposed group (mild or no hot flashes), at least eight repeated measures per woman, a type I > error of 5%, and a within-woman correlation of 0.4 for 80% power to detect an OR of 1.93 for risk factors with a low prevalence of 20%. The detectible OR is 1.76 for risk factors with a prevalence of 30% and is even lower for risk factors with prevalence greater than 30%. For our exploratory aim of identifying predictors of short versus long continuation of moderate/severe hot flashes, approximately 35% of the 158 women were classified in the short continuation subgroup, as defined by moderate/severe hot flashes that ended within 3 years after the FMP. We examined which subject-level risk factors with prevalence of 20% to 50% were associated with short continuation compared with long continuation after menopause. We assumed that 25% of women had short continuation of hot flashes in the unexposed group, with similar assumptions as above. Based on available data, there is 80% power to detect ORs of 3.6 to j2.77, respectively, in the exploratory analysis. Power is greater for continuous risk factors.
All analyses were conducted using the SAS 9.3 statistical package (SAS Inc, Cary, NC). Statistical tests were two-sided, with P e 0.05 considered significant.
RESULTS
Sample description
Two hundred fifty-five participants were followed for 16 years, with 15.1 mean outcome reports per participant and 1,336 person-years of follow-up after the last menstrual period. During follow-up, 203 women (80%) reported moderate/severe hot flashes, 44 women (17%) had only mild hot flashes, and 8 women (3%) reported no hot flashes. The mean (SD) age was 42.16 (3.38) years at baseline and 51.47 (3.32) years at the FMP; 49% were African American and 51% were white ( Table 1) .
Prevalence of hot flashes in relation to FMP
The peak prevalence of moderate/severe hot flashes was 46% and occurred in the first 2 years after the FMP (Fig. 1 ). Ten years before the FMP, the prevalence was 16% and increased to 32% in the year before the FMP. The prevalence of moderate/severe hot flashes decreased slowly after the peak years. Return to premenopausal levels did not occur until approximately 10 years after the FMP, when the prevalence (32%) was the same as that in the year before the FMP.
The peak prevalence of any hot flashes (mild, moderate, or severe) was approximately 74% and likewise occurred in the first 2 years after the FMP. Ten years before the FMP, the prevalence was 32% and increased to 58% in the year before the FMP. Return to premenopausal levels did not occur until 5 to 9 years after the FMP, when the prevalence of any hot flashes was approximately 58%, the same prevalence as in the year before the FMP.
Hot flash duration after FMP
In the subgroup of 182 women who reported moderate/ severe hot flashes after the FMP, the mean (SD) duration of hot flashes after the FMP was 4.6 (2.9) years. The mean (SD) duration of any hot flashes (mild, moderate, or severe; n = 230) after the FMP was only slightly longer at 4.9 (3.1) years. Ten percent (25 of 255) of the participants had no hot flashes after the FMP. The total mean (SD) duration of moderate/severe hot flashes from initial onset to observed endpoint was nearly two times longer at 8.8 (4.4) years. The total mean (SD) duration of any hot flashes was 10.2 (4.2) years ( Table 2 ). Table 3 shows the associations of a priori covariates with moderate/severe hot flashes in a time-adjusted analysis. The prevalence of moderate/severe hot flashes was significantly associated with time in all models. Compared with early postmenopause (FMP + 5 y), the risk of hot flashes was 66% lower before the FMP but only 29% lower in late postmenopause (Q6 y after the FMP), a further indication of the slow decline in the risk of hot flashes (OR, 0.34; 95% CI, 0.28-0.41; P G 0.001 and OR, 0.71; 95% CI, 0.52-0.97; P = 0.003, respectively).
Associations with time and hormone levels
FSH had a strong interaction with time in relation to hot flashes (P G 0.001), indicating that the risk of hot flashes increased by 63% with each 1-SD increase in log FSH before the FMP (OR, 1.63; 95% CI, 1.45-1.83; P G 0.001) in multivariable analysis ( Table 4 ). The association of FSH with hot flashes was not significant after the FMP (ie, early postmenopause stage and late postmenopause stage at Q6 y), when further FSH increases were moderate and stabilized at postmenopausal levels (Fig. 2) . Estradiol was evaluated separately in the multivariable model and had no significant interaction with time. Each unit (SD) decrease in log estradiol during the study interval resulted in a 14% increase in the risk of hot flashes (OR, 0.86; 95% CI, 0.77-0.96; P = 0.008).
A significant interaction between BMI and race (P = 0.01) in relation to hot flashes indicated that African-American women (both obese and nonobese) and obese white women had the greatest risk of moderate/severe hot flashes during the study interval, whereas nonobese white women had the lowest risk ( Table 4 , Fig. 3 ). Among the four subgroups, there was no significant difference in age at the FMP or duration of hot flashes after the FMP (Table 2 ). However, African-American women had a longer mean (SD) total duration of hot flashes (9.5 [4.3] vs 8.1 [4.4] y for white women, P = 0.03), suggesting that the racial difference in the risk of hot flashes occurred before the FMP.
Anxiety remained a significant risk factor for hot flashes in multivariable analysis, with a 5% increased risk for each point increase in anxiety score during the study period. Higher education levels were protective, with a 34% lower risk of hot flashes among women with education beyond high school (Table 4 ). Age at the FMP was included in all multivariable models but was not significant and added no additional information to the variable of time. Depressed mood (Center for Epidemiologic StudiesVDepression Scale), history of depression, perceived stress, and poorer physical health were significantly associated with hot flashes in unadjusted analysis (Table 3) , but not in multivariable analysis, caused in part by their high correlations with anxiety. Current smoking, alcohol use, and employment had no significant association with moderate/severe hot flashes across time relative to the FMP.
The analyses were repeated to estimate associations with moderate/severe hot flashes using the earlier cutoff point of 3 years or more after the FMP; results were nearly identical to those shown in Tables 3 and 4 . The analyses were also repeated to estimate associations with any hot flashes (mild, moderate, or severe); results were consistent with those shown in Tables 3 and 4 .
Predictors of short versus long continuation of hot flashes after FMP
We explored whether risk factors measured before the FMP predicted a short or long continuation of hot flashes after the FMP. The cutoff point was at 3 years after the FMP, as Race-BMI interaction, P = 0.018. defined above. Only race remained a significant predictor after adjusting for all other variables in the model in this subgroup analysis. African-American women were more than twice as likely as white women to belong to the long-term group (OR, 2.17; 95% CI, 0.99-4.78; P = 0.05). Contrary to our expectation, the duration of hot flashes before the FMP did not predict a short or long continuation of hot flashes after the FMP (OR, 1.05; 95% CI, 0.93-1.17; P = 0.38).
DISCUSSION
The mean duration of moderate/severe hot flashes after the FMP was more than 4.5 years in this population-based sample that was followed for 16 years. The prevalence of hot flashes peaked in the year after the FMP, but the mean prevalence of moderate/severe hot flashes did not return to its level before the FMP until approximately 10 years later. When the total duration of hot flashes was considered, including time before the FMP, the mean duration of moderate/severe hot flashes was nearly 9 years. These findings are consistent with other recent reports of the duration of hot flashes 5<8,18 and add further evidence that many women may experience hot flashes considerably longer than several years after menopause.
Hormone levels were significantly associated with hot flashes during the study interval. It is noteworthy that increasing FSH levels were strongly associated with hot flashes before the FMP but not in the early or late postmenopausal stages. We speculate that the strong interaction between FSH and hot flashes was attributable to the large increase in FSH levels that occurred before the FMP (ie, the first time interval in the study), when FSH levels approximately doubled (Fig. 2) , whereas there was much less increase in FSH levels after the FMP as FSH gradually stabilized at postmenopausal levels. Estradiol had a weaker association with hot flashes during the study interval, but the pattern of estradiol across time seemed to be notably similar to its pattern in the detailed hormone studies by Burger et al 19 and Randolph et al. 20 We observed that the largest decrease in estradiol levels occurred approximately between year j2 and year +3 around the FMP, which Randolph et al 20 identified as a significant decrease. These findings add support to their conclusion that the hormone patterns around the FMP were a relatively consistent process in ovarian aging and were not associated with age at the FMP. Further studies might determine whether remission of hot flashes occurs after this observed decrease in estradiol levels as estradiol levels stabilize at postmenopausal levels.
The association of race with hot flashes was consistent with previous studies that found African-American women to be more likely to report hot flashes. 21<25 These findings added that African-American women had a longer total duration of hot flashes compared with white women, but that neither age at the FMP nor duration of hot flashes after the FMP differed between the two racial groups. Taken together, the findings suggested that racial differences in hot flashes occurred before menopause, consistent with our previous studies where African-American women had earlier onset of hot flashes and lower estradiol levels in the premenopausal stage compared with white women. 26 We know of no demonstrated explanation for lower estradiol levels in African-American premenopausal women but speculate that differences in body composition and lean body mass contribute to lower estradiol levels and earlier onset of hot flashes.
In this study, BMI significantly modified the racial association with hot flashes, but the association was complex. Obese African-American women and obese white women, but also nonobese African-American women, had a greater risk of hot flashes. Again, we speculate that the increased risk of hot flashes in obese women was associated with their lower estradiol levels before menopause (and earlier onset of hot flashes), as previously identified, 26, 27 but the finding that nonobese African-American women also had a greater risk of hot flashes remains unexplained. A report from the Study of Women's Health Across the Nation indicated that African-American women were more likely to report hot flashes and also had greater symptom sensitivity, supporting postulates that cultural differences affect hot flash reporting, but further evidence is needed. 21 Anxiety symptoms have been identified as a strong risk factor for hot flashes, 8,10,21,28<30 but it is not known whether anxiety amplifies, or is primarily a predictor of, hot flashes. 31 It has also been suggested that the association between anxiety symptoms and hot flashes is attributable to an overlap of somatic symptoms of both disorders rather than to the psychological condition of anxiety. 30 Both anxiety and hot flashes have physiologic and psychological components that are difficult to disentangle, and whether anxiety is associated with responses to hot flash treatments is also not known. An Table 4 .
increased understanding of the role of anxiety in hot flashes might lead to treatments that reduce both anxiety and hot flashes, but further studies evaluating these issues are needed.
The finding that smoking was not associated with a risk of long-term hot flashes was consistent with other studies that found no relationship between smoking and hot flash duration. 5, 8 Previous findings in our cohort indicated that smokers were more likely to experience hot flashes 32 and had an increased risk of entry into the menopausal transition, 33 and that genetic susceptibility played a role in smoking associations with hot flashes. 34 The cohort has a high proportion of current smokers (40% vs 18% for adult women in the United States 35 ), and smoking has been clearly associated with earlier menopause, possibly owing to its antiestrogenic effects, 34, 36 but it seems that smoking was not a factor in the risk of hot flashes after the FMP.
A limitation of the study is that current users of hormone therapy and women who had had surgical menopause were not included; further studies identifying associations between these conditions and hot flash duration are needed. Our evaluation of risk factors for a short or long continuation of hot flashes after the FMP was conducted in a smaller subgroup with limited power; thus, results should be interpreted with caution. A number of women continued to report hot flashes at study endpoint, and it is possible that longer follow-up would increase the prevalence and risks of hot flashes after the FMP. Although we evaluated multiple risk factors known to be associated with hot flashes, other variables may be important. Our findings are based on a population-based cohort of African-American and white urban women who were in generally good health with no current hormone use; thus, they may not be generalizable to all perimenopausal women.
The primary strengths of this report are the evaluation of hot flashes in relation to time before and after the FMP during a 16-year period. All participants were premenopausal at baseline and reached menopause during the study, which provided a clear identification of menopause with minimal recall bias. The population-based sample was randomly identified and stratified to have similar numbers of African-American and white women for analysis of racial associations. The repeated measures of hot flash reports and hormones were concomitant, and the multiple samples for hormone assays were collected in the early follicular phase in menstruating women for consistent assessments.
CONCLUSIONS
This study shows that women can expect hot flashes to continue, on average, for 4 to 5 years after the FMP, and that some women will experience moderate/severe hot flashes for more than 10 years after the FMP. The risk of hot flashes is modified by clinically evaluable risk factors, including race, obesity, anxiety, and education levels. Because the natural duration of hot flashes can exceed the duration (3-5 y) recommended for hormone therapy, it is not surprising that women may experience a return of hot flashes after discontinuing hormone therapy, although this requires further studies. The findings point to the importance of individualized treatmentVconsidering the potential duration of hot flashes together with increasing evidence of effective treatment options 4, 37 Vwhen managing postmenopausal women.
